A newly published peer-reviewed study in JAMA Internal Medicine examines what happens to patients' weight after they stop taking tirzepatide — the active ingredient in Mounjaro and Zepbound. The findings add important context for the millions of people currently on GLP-1 medications who wonder what discontinuing treatment might mean for their long-term health.
What the Research Looks At
The study, published in JAMA Internal Medicine, focuses specifically on weight regain following tirzepatide withdrawal. Tirzepatide is a dual GIP and GLP-1 receptor agonist — meaning it activates two hormone pathways involved in appetite regulation and blood sugar control, rather than one. The publication joins a growing body of research examining what happens to the body when these powerful medications are stopped.
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide work by mimicking hormones that regulate hunger and fullness. When patients stop taking them, those hormonal signals diminish, which can affect appetite and metabolism.
Why Weight Regain After Stopping Is a Known Concern
Research on GLP-1 medications has consistently shown that obesity is a chronic condition requiring ongoing management. When patients stop GLP-1 or dual GIP/GLP-1 therapies, the biological drivers of weight gain — including appetite hormones and metabolic rate — can reassert themselves. This is not a matter of willpower; it reflects how these medications interact with the body's weight-regulating systems.
The JAMA Internal Medicine publication specifically addresses tirzepatide withdrawal, providing clinicians and patients with a clearer picture of what the discontinuation trajectory may look like for people taking Mounjaro or Zepbound.
Key takeaway: Weight regain after stopping tirzepatide appears to be a documented clinical concern, according to new research in JAMA Internal Medicine — reinforcing that GLP-1 and dual GIP/GLP-1 medications may need to be part of a long-term treatment plan rather than a short-term fix.
What This Means for Patients on GLP-1 Medications
If you are currently taking Ozempic, Wegovy, Mounjaro, or Zepbound, this research has practical implications:
- Stopping is not without consequences. Weight regain following discontinuation is a recognized medical phenomenon, not a personal failure.
- Decisions to stop should involve your prescriber. Whether due to cost, side effects, or personal preference, ending treatment is a medical decision that warrants a conversation with your doctor about what to expect.
- Lifestyle factors still matter. Diet and physical activity habits built during treatment can help slow regain, though they may not fully offset it once medication stops.
What to Watch For Next
As more peer-reviewed data emerges on GLP-1 and dual agonist discontinuation, researchers and clinicians will be looking at several open questions: how quickly weight returns after stopping, whether certain patient profiles experience more or less regain, and what strategies — including restarting medication — best support long-term weight management. The JAMA Internal Medicine publication adds an important data point to this evolving conversation.
Frequently Asked Questions
As always, any decisions about starting, continuing, or stopping a GLP-1 medication should be made in close consultation with your prescribing clinician, who can provide guidance tailored to your individual health needs and goals.
- Peer-reviewed journal article, 'What Happens When You Stop Your GLP-1 Weight Loss Drug? Understanding Weight Regain After Tirzepatide Withdrawal,' JAMA Internal Medicine